Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free:

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site:, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Google Analytics

Targeted advertising cookies


The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at or by post at:

24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

Dr Céline Jousse

Céline Jousse's profile

Field of research

Metabolic diseases have multiple origins ranging from genetic and environmental factors. A key feature characteristic of these diseases is that transient environmental influences such as a nutritional stress during perinatal life may induce deleterious heritable health effects that may last for the entire life of individual. This "nutritional programming" has also been reported in animals but the molecular mechanisms involved are not understood. Since the consequences of the events occurring in early life are maintained throughout life, epigenetic modifications are likely to play an important role in this process. Among these modifications, DNA methylation is the best-studied and has been shown to be affected by various environmental stimuli.

Research activities

In that context, the aim of this proposal is to identify epigenetic biomarkers that may be used to identify at risk population in human and signaling pathways affected by epigenetic regulation; these pathways could be considered as potential drug target. The most efficient way to identify such biomarkers is to rely on animal models in which we have developed a particular strategy leading to the identification of specific markers. Three main questions will be addressed in this project: (i) Identification of key specific epigenetic marks (methylation) correlated with the onset of metabolic diseases, such as diabetes or obesity, using a pertinent mice model. (ii) Identification of orthologous regions in human using bioinformatics tools and samples from appropriate cohorts to provide predictive and diagnostic markers (iii) identification of genes networks that may be affected by the epigenetic marks and that may constitute good candidate drug targets.

Ultimately our results may open the way to prevention and development of novel treatments associated with the epigenotype/genotype of patient leading to an efficient personalized medicine in this field and will ameliorate the quality of life at the general population level.